May 24, 2016
Sanofi said on May 23 that a subgroup analysis of a PIII study in Japan showed that its PCSK9 inhibitor alirocumab reduced LDL-C levels in diabetes patients with a high tolerability profile. According to the company, 216 patients enrolled in...read more